Drug companies use electronic signatures when submitting documents to government regulators and to business partners. A single standard is expected to lower costs, increase interoperability, and eliminate some proprietary standards.
The initiative for a single standard is called Secure Access for Everyone, or SAFE. Participants include major pharmaceutical companies, European and U.S. regulatory agencies, and industry groups.
To see the SAFE site, visitwww.safe-biopharma.org.